首页 > 最新文献

Hepatology Research最新文献

英文 中文
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma. 患有非病毒性慢性肝病并发展为肝细胞癌的糖尿病患者的特征。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-19 DOI: 10.1111/hepr.14124
Kyo Sasaki, Miwa Kawanaka, Yasuyuki Tomiyama, Akinobu Takaki, Motoyuki Otsuka, Fusao Ikeda, Naoko Yoshioka, Hideaki Kaneto, Jun Wada, Tetsuya Fukuda, Keisuke Hino, Sohji Nishina

Aim: Type 2 diabetes mellitus (T2DM) is a well-known risk factor for hepatocellular carcinoma (HCC). However, HCC is often diagnosed at an advanced stage in patients with diabetes because of the lack of the best criteria for surveillance candidates. The aim of this study was to identify risk factors for HCC development in patients with diabetes with nonviral chronic liver disease.

Method: Three hundred thirty T2DM patients with nonviral chronic liver disease who underwent surveillance for HCC by imaging techniques between 2009 and 2020 were enrolled in this multicenter cross-sectional retrospective study. The clinical and laboratory parameters of patients with and without HCC were compared.

Results: Age ≥65 years, alcohol intake, lack of hepatic steatosis, triglyceride level <111 mg/dL, Mac2 binding protein glycosylation isomer (M2BPGi) ≥0.9 cut-off index (COI), α-fetoprotein concentration ≥5 ng/mL, and des-γ-carboxy prothrombin concentration ≥26 mAU/mL were independently associated with HCC development. When stratified by age, only alcohol intake (odds ratio [OR] 114.19, p < 0.001) was associated with HCC development in patients aged <65 years, and medication for diabetes mellitus (OR 5.72, p = 0.001), lack of hepatic steatosis (OR 4.47, p = 0.002), lactate dehydrogenase ≥198 IU/L (OR 2.751, p = 0.031), M2BPGi ≥1.18 COI (OR 9.05, p < 0.001), and FIB-4 index ≥2.59 (OR 3.22, p = 0.017) were associated with HCC development in patients aged ≥65 years.

Conclusions: In addition to age and advanced liver fibrosis, alcohol intake in younger T2DM patients and medication for DM and lack of hepatic steatosis in older T2DM patients should be considered for HCC surveillance by imaging.

目的:众所周知,2 型糖尿病(T2DM)是肝细胞癌(HCC)的危险因素。然而,由于缺乏监测候选者的最佳标准,糖尿病患者通常在晚期才被诊断为 HCC。本研究旨在确定非病毒性慢性肝病糖尿病患者发生 HCC 的风险因素:这项多中心横断面回顾性研究共纳入了 300 名 T2DM 非病毒性慢性肝病患者,这些患者在 2009 年至 2020 年期间通过影像学技术接受了 HCC 监测。结果显示:年龄≥65 岁,酒精含量≥100 毫克/100 毫升:结果:年龄≥65 岁、酒精摄入量、无肝脂肪变性、甘油三酯水平 结论:除了年龄和晚期肝纤维化外,HCC 患者的肝脂肪变性和甘油三酯水平均高于正常人:除年龄和晚期肝纤维化外,年轻 T2DM 患者的酒精摄入量和 DM 药物治疗以及老年 T2DM 患者缺乏肝脏脂肪变性也应考虑通过造影监测 HCC。
{"title":"Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma.","authors":"Kyo Sasaki, Miwa Kawanaka, Yasuyuki Tomiyama, Akinobu Takaki, Motoyuki Otsuka, Fusao Ikeda, Naoko Yoshioka, Hideaki Kaneto, Jun Wada, Tetsuya Fukuda, Keisuke Hino, Sohji Nishina","doi":"10.1111/hepr.14124","DOIUrl":"https://doi.org/10.1111/hepr.14124","url":null,"abstract":"<p><strong>Aim: </strong>Type 2 diabetes mellitus (T2DM) is a well-known risk factor for hepatocellular carcinoma (HCC). However, HCC is often diagnosed at an advanced stage in patients with diabetes because of the lack of the best criteria for surveillance candidates. The aim of this study was to identify risk factors for HCC development in patients with diabetes with nonviral chronic liver disease.</p><p><strong>Method: </strong>Three hundred thirty T2DM patients with nonviral chronic liver disease who underwent surveillance for HCC by imaging techniques between 2009 and 2020 were enrolled in this multicenter cross-sectional retrospective study. The clinical and laboratory parameters of patients with and without HCC were compared.</p><p><strong>Results: </strong>Age ≥65 years, alcohol intake, lack of hepatic steatosis, triglyceride level <111 mg/dL, Mac2 binding protein glycosylation isomer (M2BPGi) ≥0.9 cut-off index (COI), α-fetoprotein concentration ≥5 ng/mL, and des-γ-carboxy prothrombin concentration ≥26 mAU/mL were independently associated with HCC development. When stratified by age, only alcohol intake (odds ratio [OR] 114.19, p < 0.001) was associated with HCC development in patients aged <65 years, and medication for diabetes mellitus (OR 5.72, p = 0.001), lack of hepatic steatosis (OR 4.47, p = 0.002), lactate dehydrogenase ≥198 IU/L (OR 2.751, p = 0.031), M2BPGi ≥1.18 COI (OR 9.05, p < 0.001), and FIB-4 index ≥2.59 (OR 3.22, p = 0.017) were associated with HCC development in patients aged ≥65 years.</p><p><strong>Conclusions: </strong>In addition to age and advanced liver fibrosis, alcohol intake in younger T2DM patients and medication for DM and lack of hepatic steatosis in older T2DM patients should be considered for HCC surveillance by imaging.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal transplant strategy of pediatric liver transplantation for fibropolycystic liver disease: Multicenter retrospective study in Japan. 纤维囊性肝病小儿肝移植的最佳移植策略:日本多中心回顾性研究。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-15 DOI: 10.1111/hepr.14122
Hajime Uchida, Ayano Inui, Tatsuya Okamoto, Toshihiro Yasui, Masaki Honda, Koichi Mizuta, Kazuhiko Bessho, Hideaki Okajima, Takehisa Ueno, Toshiharu Matsuura, Noriki Okada, Seisuke Sakamoto, Mureo Kasahara

Aim: To assess the preoperative disease characteristics and indications for living donor liver transplantation (LDLT), complications, patient survival, and prognosis after LDLT for fibropolycystic liver disease (FLD) in children.

Methods: We undertook a cross-sectional survey of patients who underwent LDLT for FLD between January 2002 and December 2020.

Results: A total of 35 patients (22 male and 13 female individuals) with FLD were included in this study, of whom 19 (54.3%) had isolated congenital hepatic fibrosis and 16 (45.6%) had Caroli syndrome. Refractory gastrointestinal bleeding was the most frequent symptom related to the indication for LDLT, being found in 48.6% of our patients, followed by uncontrollable cholangitis and ascites. The median age at the time of LDLT was 8.1 years old. Of the 27 patients presenting with renal involvement, 13 patients required kidney transplantation (KT). Overall, the renal function after LDLT decreased regardless of renal involvement; however, patients with renal involvement had a significantly lower estimated glomerular filtration rate than those without renal involvement throughout the course of this study (p < 0.01). The 5-year overall patient survival rate was 97.1%. Two patients died with a median follow-up of 8.9 years after LDLT; one died due to sepsis 2 weeks after simultaneous liver-kidney transplantation and the other committed suicide 10 years after LDLT.

Conclusion: The prognosis of the pediatric patients who underwent LDLT for FLD was excellent. However, an individualized treatment approach based on the status of the renal function and liver disease is important, as a certain proportion of patients require KT.

目的:评估儿童纤维囊性肝病(FLD)的术前疾病特征、活体肝移植(LDLT)适应症、并发症、患者生存率以及LDLT术后预后:我们对2002年1月至2020年12月期间接受LDLT治疗的FLD患者进行了横断面调查:本研究共纳入35名FLD患者(22名男性和13名女性),其中19人(54.3%)患有孤立性先天性肝纤维化,16人(45.6%)患有卡罗利综合征。难治性消化道出血是与 LDLT 适应症相关的最常见症状,在我们的患者中占 48.6%,其次是无法控制的胆管炎和腹水。接受 LDLT 时的中位年龄为 8.1 岁。在出现肾脏受累的 27 名患者中,有 13 名患者需要进行肾移植(KT)。总体而言,无论肾脏受累与否,LDLT 后的肾功能都会下降;但在整个研究过程中,肾脏受累患者的估计肾小球滤过率明显低于无肾脏受累的患者(P 结论:LDLT 后的肾功能下降与肾脏受累无关,但在整个研究过程中,肾脏受累患者的估计肾小球滤过率明显低于无肾脏受累的患者:接受 LDLT 治疗 FLD 的儿童患者预后良好。然而,由于一定比例的患者需要接受 KT,因此根据肾功能和肝病状况采取个体化治疗方法非常重要。
{"title":"Optimal transplant strategy of pediatric liver transplantation for fibropolycystic liver disease: Multicenter retrospective study in Japan.","authors":"Hajime Uchida, Ayano Inui, Tatsuya Okamoto, Toshihiro Yasui, Masaki Honda, Koichi Mizuta, Kazuhiko Bessho, Hideaki Okajima, Takehisa Ueno, Toshiharu Matsuura, Noriki Okada, Seisuke Sakamoto, Mureo Kasahara","doi":"10.1111/hepr.14122","DOIUrl":"https://doi.org/10.1111/hepr.14122","url":null,"abstract":"<p><strong>Aim: </strong>To assess the preoperative disease characteristics and indications for living donor liver transplantation (LDLT), complications, patient survival, and prognosis after LDLT for fibropolycystic liver disease (FLD) in children.</p><p><strong>Methods: </strong>We undertook a cross-sectional survey of patients who underwent LDLT for FLD between January 2002 and December 2020.</p><p><strong>Results: </strong>A total of 35 patients (22 male and 13 female individuals) with FLD were included in this study, of whom 19 (54.3%) had isolated congenital hepatic fibrosis and 16 (45.6%) had Caroli syndrome. Refractory gastrointestinal bleeding was the most frequent symptom related to the indication for LDLT, being found in 48.6% of our patients, followed by uncontrollable cholangitis and ascites. The median age at the time of LDLT was 8.1 years old. Of the 27 patients presenting with renal involvement, 13 patients required kidney transplantation (KT). Overall, the renal function after LDLT decreased regardless of renal involvement; however, patients with renal involvement had a significantly lower estimated glomerular filtration rate than those without renal involvement throughout the course of this study (p < 0.01). The 5-year overall patient survival rate was 97.1%. Two patients died with a median follow-up of 8.9 years after LDLT; one died due to sepsis 2 weeks after simultaneous liver-kidney transplantation and the other committed suicide 10 years after LDLT.</p><p><strong>Conclusion: </strong>The prognosis of the pediatric patients who underwent LDLT for FLD was excellent. However, an individualized treatment approach based on the status of the renal function and liver disease is important, as a certain proportion of patients require KT.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic performance of a two-step method using the Fibro-Scope system for metabolic dysfunction-associated steatotic liver disease. 使用纤维镜系统的两步法检测代谢功能障碍相关脂肪肝的预后性能。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-15 DOI: 10.1111/hepr.14121
Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Saiyu Tanaka, Takao Shirono, Yusuke Takahashi, Kento Takeuchi, Seita Kataoka, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh

Aim: Fibro-Scope is an artificial intelligence/neural network system for the noninvasive diagnosis of hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. We aimed to examine the diagnostic performance of a two-step method that used the Fibrosis-4 (FIB-4) index and Fibro-Scope system for the assessment of Japanese patients with metabolic dysfunction-associated steatotic liver disease.

Methods: We analyzed a longitudinal study cohort of 796 Japanese patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease during a follow-up period of 6.4 years. The predictive performance of the two-step method of FIB-4 index and Fibro-Scope for liver-related events and prognostic performance of that were assessed in the patients.

Results: In the 796 patients, by classifying the intermediate zone, defined by FIB-4 index 1.30-2.67, using the Fibro-Scope, the final classification was 69.6% low risk, 28.3% high risk, and 2.1% in the middle-risk group. The sensitivity and specificity for predicting advanced fibrosis (≥F3) was 84.0% and 84.0%. During the follow-up period, 52 (6.5%) patients developed liver-related events and 35 died. Multivariate analysis revealed that high-risk patients derived from the two-step method had hazard ratios of 30.1 or the development of liver-related events and 7.8 for outcome.

Conclusions: The two-step method using the FIB-4 index and Fibro-Scope contributed to improving the diagnostic performance by picking up high-risk patients from those classified as intermediate risk with the FIB-4 index. This noninvasive method, which uses a blood sample is a cost-effective screening method, is suitable for clinical practice in Japan.

目的:Fibro-Scope 是一种人工智能/神经网络系统,用于无创诊断代谢功能障碍相关性脂肪肝患者的肝纤维化。我们的目的是研究使用纤维化-4(FIB-4)指数和 Fibro-Scope 系统评估日本代谢功能障碍相关脂肪性肝病患者的两步法的诊断性能:我们对 796 名经活检证实患有代谢功能障碍相关性脂肪肝的日本患者进行了为期 6.4 年的纵向研究分析。研究人员评估了 FIB-4 指数和 Fibro-Scope 两步法对肝脏相关事件的预测性和预后性:在796名患者中,通过使用Fibro-Scope对FIB-4指数为1.30-2.67的中间区进行分类,最终69.6%的患者属于低危,28.3%的患者属于高危,2.1%的患者属于中危组。预测晚期纤维化(≥F3)的敏感性和特异性分别为 84.0% 和 84.0%。在随访期间,有52名患者(6.5%)发生了肝脏相关事件,35人死亡。多变量分析显示,两步法得出的高危患者发生肝脏相关事件的危险比为30.1,死亡的危险比为7.8:结论:使用FIB-4指数和纤维镜的两步法有助于从FIB-4指数归类为中危的患者中挑选出高危患者,从而提高诊断效果。这种使用血液样本的无创方法是一种经济有效的筛查方法,适合日本的临床实践。
{"title":"Prognostic performance of a two-step method using the Fibro-Scope system for metabolic dysfunction-associated steatotic liver disease.","authors":"Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Saiyu Tanaka, Takao Shirono, Yusuke Takahashi, Kento Takeuchi, Seita Kataoka, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh","doi":"10.1111/hepr.14121","DOIUrl":"https://doi.org/10.1111/hepr.14121","url":null,"abstract":"<p><strong>Aim: </strong>Fibro-Scope is an artificial intelligence/neural network system for the noninvasive diagnosis of hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. We aimed to examine the diagnostic performance of a two-step method that used the Fibrosis-4 (FIB-4) index and Fibro-Scope system for the assessment of Japanese patients with metabolic dysfunction-associated steatotic liver disease.</p><p><strong>Methods: </strong>We analyzed a longitudinal study cohort of 796 Japanese patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease during a follow-up period of 6.4 years. The predictive performance of the two-step method of FIB-4 index and Fibro-Scope for liver-related events and prognostic performance of that were assessed in the patients.</p><p><strong>Results: </strong>In the 796 patients, by classifying the intermediate zone, defined by FIB-4 index 1.30-2.67, using the Fibro-Scope, the final classification was 69.6% low risk, 28.3% high risk, and 2.1% in the middle-risk group. The sensitivity and specificity for predicting advanced fibrosis (≥F3) was 84.0% and 84.0%. During the follow-up period, 52 (6.5%) patients developed liver-related events and 35 died. Multivariate analysis revealed that high-risk patients derived from the two-step method had hazard ratios of 30.1 or the development of liver-related events and 7.8 for outcome.</p><p><strong>Conclusions: </strong>The two-step method using the FIB-4 index and Fibro-Scope contributed to improving the diagnostic performance by picking up high-risk patients from those classified as intermediate risk with the FIB-4 index. This noninvasive method, which uses a blood sample is a cost-effective screening method, is suitable for clinical practice in Japan.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of the nervous system in liver diseases 神经系统在肝病中的作用。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-11 DOI: 10.1111/hepr.14125
Boris Mravec, Maria Szantova

The nervous system significantly participates in maintaining homeostasis, and modulating repair and regeneration processes in the liver. Moreover, the nervous system also plays an important role in the processes associated with the development and progression of liver disease, and can either potentiate or inhibit these processes. The aim of this review is to describe the mechanisms and pathways through which the nervous system influences the development and progression of liver diseases, such as alcohol-associated liver disease, nonalcoholic fatty liver disease, cholestatic liver disease, hepatitis, cirrhosis, and hepatocellular carcinoma. Possible therapeutic implications based on modulation of signals transduction between the nervous system and the liver are also discussed.

神经系统在维持肝脏平衡、调节肝脏修复和再生过程中发挥着重要作用。此外,神经系统在与肝病的发生和发展相关的过程中也发挥着重要作用,可以促进或抑制这些过程。本综述旨在描述神经系统影响肝病(如酒精相关性肝病、非酒精性脂肪肝、胆汁淤积性肝病、肝炎、肝硬化和肝细胞癌)发生和发展的机制和途径。此外,还讨论了通过调节神经系统与肝脏之间的信号转导可能产生的治疗效果。
{"title":"The role of the nervous system in liver diseases","authors":"Boris Mravec,&nbsp;Maria Szantova","doi":"10.1111/hepr.14125","DOIUrl":"10.1111/hepr.14125","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>The nervous system significantly participates in maintaining homeostasis, and modulating repair and regeneration processes in the liver. Moreover, the nervous system also plays an important role in the processes associated with the development and progression of liver disease, and can either potentiate or inhibit these processes. The aim of this review is to describe the mechanisms and pathways through which the nervous system influences the development and progression of liver diseases, such as alcohol-associated liver disease, nonalcoholic fatty liver disease, cholestatic liver disease, hepatitis, cirrhosis, and hepatocellular carcinoma. Possible therapeutic implications based on modulation of signals transduction between the nervous system and the liver are also discussed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world trends in acute viral hepatitis in Japan: A nationwide questionnaire-based survey. 日本急性病毒性肝炎的现实趋势:全国范围内的问卷调查。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-10 DOI: 10.1111/hepr.14123
Kazuya Okushin, Tatsuya Kanto, Masaaki Korenaga, Kazuhiko Ikeuchi, Toshiyuki Kishida, Akira Kado, Mitsuhiro Fujishiro, Takeya Tsutsumi, Tomoyuki Takura, Hiroshi Yotsuyanagi

Aim: The actual incidence of acute viral hepatitis in Japan remains unclear. We aimed to investigate trends in the incidence of acute hepatitis B and C infections in Japan.

Methods: A nationwide, multicenter, retrospective questionnaire-based survey was conducted. Participating hospitals received questionnaires through nationwide geographically distributed regional core centers certified as specialists in hepatitis treatment. The questionnaire included hospital size and the number of patients diagnosed with acute hepatitis B or C during each fiscal year (FY) from 2015 to 2022. The sex distribution in each FY was also documented. Comparisons were made before and during the COVID-19 era (2015-2019 vs. 2020-2022), and between populous and non-populous prefectures.

Results: Responses to the questionnaires were obtained from 127 institutions in 29 prefectures covering eight regions in Japan. A median of 127.0 patients with acute hepatitis B (interquartile range [IQR] 106.5-131.8 patients) were reported during each FY, and the incidence significantly decreased during the fiscal years 2020-2022 compared with the fiscal years 2015-2020 (median 96.0 [IQR 91.0-103.0] patients vs. 131.0 [IQR 128.0-134.0] patients; p = 0.03). A median of 10.0 (IQR, 7.8-13.5) patients were reported with acute hepatitis C during each FY. The proportions of men in acute hepatitis B and C were significantly higher in populous prefectures.

Conclusions: Populous prefectures had a higher proportion of men among viral hepatitis patients than non-populous prefectures. Estimating the high-risk populations in each area could provide insights to advance the elimination of viral hepatitis.

目的:日本急性病毒性肝炎的实际发病率仍不清楚。我们旨在调查日本急性乙型和丙型肝炎感染率的变化趋势:方法:我们在全国范围内开展了一项多中心回顾性问卷调查。参与调查的医院通过在全国范围内按地域分布的经认证的肝炎治疗专家区域核心中心接收问卷。问卷内容包括医院规模以及 2015 年至 2022 年每个财政年度(FY)确诊的急性乙型或丙型肝炎患者人数。每个财政年度的性别分布情况也被记录在案。在 COVID-19 时代(2015-2019 年与 2020-2022 年)之前和期间进行了比较,并在人口众多的都道府县和非人口众多的都道府县之间进行了比较:日本 8 个地区 29 个都道府县的 127 家机构对调查问卷进行了回复。每个财政年度报告的急性乙型肝炎患者中位数为 127.0 人(四分位数间距 [IQR] 106.5-131.8 人),与 2015-2020 财政年度相比,2020-2022 财政年度的发病率显著下降(中位数 96.0 [IQR 91.0-103.0] 人 vs. 131.0 [IQR 128.0-134.0] 人;p = 0.03)。每个财政年度报告的急性丙型肝炎患者中位数为 10.0(IQR,7.8-13.5)人。在人口众多的都道府县,急性乙型和丙型肝炎患者中男性的比例明显更高:结论:与非人口大县相比,人口大县的病毒性肝炎患者中男性比例更高。对每个地区的高危人群进行估计可为推动消除病毒性肝炎提供启示。
{"title":"Real-world trends in acute viral hepatitis in Japan: A nationwide questionnaire-based survey.","authors":"Kazuya Okushin, Tatsuya Kanto, Masaaki Korenaga, Kazuhiko Ikeuchi, Toshiyuki Kishida, Akira Kado, Mitsuhiro Fujishiro, Takeya Tsutsumi, Tomoyuki Takura, Hiroshi Yotsuyanagi","doi":"10.1111/hepr.14123","DOIUrl":"https://doi.org/10.1111/hepr.14123","url":null,"abstract":"<p><strong>Aim: </strong>The actual incidence of acute viral hepatitis in Japan remains unclear. We aimed to investigate trends in the incidence of acute hepatitis B and C infections in Japan.</p><p><strong>Methods: </strong>A nationwide, multicenter, retrospective questionnaire-based survey was conducted. Participating hospitals received questionnaires through nationwide geographically distributed regional core centers certified as specialists in hepatitis treatment. The questionnaire included hospital size and the number of patients diagnosed with acute hepatitis B or C during each fiscal year (FY) from 2015 to 2022. The sex distribution in each FY was also documented. Comparisons were made before and during the COVID-19 era (2015-2019 vs. 2020-2022), and between populous and non-populous prefectures.</p><p><strong>Results: </strong>Responses to the questionnaires were obtained from 127 institutions in 29 prefectures covering eight regions in Japan. A median of 127.0 patients with acute hepatitis B (interquartile range [IQR] 106.5-131.8 patients) were reported during each FY, and the incidence significantly decreased during the fiscal years 2020-2022 compared with the fiscal years 2015-2020 (median 96.0 [IQR 91.0-103.0] patients vs. 131.0 [IQR 128.0-134.0] patients; p = 0.03). A median of 10.0 (IQR, 7.8-13.5) patients were reported with acute hepatitis C during each FY. The proportions of men in acute hepatitis B and C were significantly higher in populous prefectures.</p><p><strong>Conclusions: </strong>Populous prefectures had a higher proportion of men among viral hepatitis patients than non-populous prefectures. Estimating the high-risk populations in each area could provide insights to advance the elimination of viral hepatitis.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
c-Met inhibitor upregulates E-cadherin, which is lost in portal vein tumor thrombus of hepatocellular carcinoma. c-Met 抑制剂能上调肝癌门静脉瘤栓中丢失的 E-cadherin。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-05 DOI: 10.1111/hepr.14120
Satoru Abe, Yoshinori Inagaki, Takashi Kokudo, Akinori Miyata, Yujiro Nishioka, Akihiko Ichida, Junichi Kaneko, Nobuhisa Akamatsu, Yoshikuni Kawaguchi, Kiyoshi Hasegawa

Aim: Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is an essential therapeutic and prognostic factor. E-cadherin plays a crucial role in adhesive properties and intercellular interaction in various cancer tissues, including HCC, but the expression profile and functional contribution of E-cadherin in PVTT remain unknown. This study aimed to analyze the expression of E-cadherin in the main tumor tissue and PVTT tissue of HCC, and evaluate the functional roles of E-cadherin in PVTT formation.

Methods: A retrospective analysis was performed using the medical records of patients who underwent liver resection for HCC with PVTT, analyzing tissue specimens from 1995 to 2016. E-cadherin expression is evaluated using immunohistochemistry and western blot. The study also uses a c-Met inhibitor to explore its impact on E-cadherin expression in vitro and in vivo using cell lines and a tumor xenograft mouse model.

Results: The results revealed a reduced E-cadherin expression in PVTT tissue than in the main tumor tissue. The inhibition of c-Met activation, frequently detected in HCC, upregulated E-cadherin expression in HCC cell lines. Furthermore, treatment with c-Met inhibitors induced changes in epithelial morphology, and inhibited migration and invasion of HCC cell lines.

Conclusions: This study demonstrates the downregulation of E-cadherin in PVTT, and underscores the potential of c-Met inhibition in upregulating E-cadherin and inhibiting metastatic behavior. Understanding the significance of E-cadherin and c-Met in HCC progression provides a foundation for future clinical investigations into the therapeutic effects of c-Met inhibitors on PVTT in HCC patients.

目的:肝细胞癌(HCC)中的门静脉瘤栓(PVTT)是一个重要的治疗和预后因素。E-cadherin 在包括 HCC 在内的各种癌症组织的粘附性和细胞间相互作用中发挥着关键作用,但 E-cadherin 在 PVTT 中的表达谱和功能贡献仍不清楚。本研究旨在分析E-cadherin在HCC主要肿瘤组织和PVTT组织中的表达,并评估E-cadherin在PVTT形成中的功能作用:利用1995年至2016年接受肝切除术的HCC伴PVTT患者的病历进行回顾性分析,分析组织标本。采用免疫组化和 Western 印迹法评估 E-cadherin 的表达。研究还使用了一种c-Met抑制剂,利用细胞系和肿瘤异种移植小鼠模型探讨其在体外和体内对E-cadherin表达的影响:结果:研究结果显示,PVTT组织中的E-cadherin表达量低于主要肿瘤组织。抑制在 HCC 中经常检测到的 c-Met 激活会上调 HCC 细胞系中 E-cadherin 的表达。此外,用 c-Met 抑制剂治疗可诱导上皮形态发生变化,并抑制 HCC 细胞株的迁移和侵袭:本研究表明,PVTT 中的 E-cadherin 下调,并强调了 c-Met 抑制剂在上调 E-cadherin 和抑制转移行为方面的潜力。了解E-adherin和c-Met在HCC进展中的重要性,为今后临床研究c-Met抑制剂对HCC患者PVTT的治疗效果奠定了基础。
{"title":"c-Met inhibitor upregulates E-cadherin, which is lost in portal vein tumor thrombus of hepatocellular carcinoma.","authors":"Satoru Abe, Yoshinori Inagaki, Takashi Kokudo, Akinori Miyata, Yujiro Nishioka, Akihiko Ichida, Junichi Kaneko, Nobuhisa Akamatsu, Yoshikuni Kawaguchi, Kiyoshi Hasegawa","doi":"10.1111/hepr.14120","DOIUrl":"https://doi.org/10.1111/hepr.14120","url":null,"abstract":"<p><strong>Aim: </strong>Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is an essential therapeutic and prognostic factor. E-cadherin plays a crucial role in adhesive properties and intercellular interaction in various cancer tissues, including HCC, but the expression profile and functional contribution of E-cadherin in PVTT remain unknown. This study aimed to analyze the expression of E-cadherin in the main tumor tissue and PVTT tissue of HCC, and evaluate the functional roles of E-cadherin in PVTT formation.</p><p><strong>Methods: </strong>A retrospective analysis was performed using the medical records of patients who underwent liver resection for HCC with PVTT, analyzing tissue specimens from 1995 to 2016. E-cadherin expression is evaluated using immunohistochemistry and western blot. The study also uses a c-Met inhibitor to explore its impact on E-cadherin expression in vitro and in vivo using cell lines and a tumor xenograft mouse model.</p><p><strong>Results: </strong>The results revealed a reduced E-cadherin expression in PVTT tissue than in the main tumor tissue. The inhibition of c-Met activation, frequently detected in HCC, upregulated E-cadherin expression in HCC cell lines. Furthermore, treatment with c-Met inhibitors induced changes in epithelial morphology, and inhibited migration and invasion of HCC cell lines.</p><p><strong>Conclusions: </strong>This study demonstrates the downregulation of E-cadherin in PVTT, and underscores the potential of c-Met inhibition in upregulating E-cadherin and inhibiting metastatic behavior. Understanding the significance of E-cadherin and c-Met in HCC progression provides a foundation for future clinical investigations into the therapeutic effects of c-Met inhibitors on PVTT in HCC patients.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up. 健康体检中代谢功能障碍相关脂肪性肝病患者的纤维化-4 指数和振动控制瞬态弹性成像肝脏硬度测量值的分布。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-04 DOI: 10.1111/hepr.14117
Yuji Ogawa, Wataru Tomeno, Yasushi Imamura, Masaru Baba, Takato Ueno, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Takaomi Kessoku, Yasushi Honda, Kazuo Notsumata, Hirotoshi Fujikawa, Megumi Kaai, Kento Imajo, Miwa Kawanaka, Hideyuki Hyogo, Mitsurou Hisatomi, Mamiko Takeuchi, Taku Hakamada, Takashi Honda, Miwa Tatsuta, Asahiro Morishita, Shigeru Mikami, Ken Furuya, Noriaki Manabe, Tomoari Kamada, Takumi Kawaguchi, Masato Yoneda, Satoru Saito, Atsushi Nakajima

Aims: The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), alcohol-associated liver disease (ALD), specific etiology, and cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check-ups. Additionally, we analyzed the distribution of Fibrosis-4 (FIB-4) index and vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM) for MASLD.

Methods: In this cross-sectional study, 6530 subjects undergoing a health check-up in Japan were included. Conventional B-mode ultrasound was carried out on all 6530 subjects, and those with MASLD underwent VCTE.

Results: The prevalence of SLD was 39.5%, comprising MASLD 28.7%, MetALD 8.6%, ALD 1.2%, specific etiology SLD 0.3%, and cryptogenic SLD 0.7%. Subjects with VCTE-derived LSM ≥8 kPa constituted 2.1% of MASLD. FIB-4 ≥1.3 showed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value for diagnosing VCTE-derived LSM ≥8 kPa were 60.6%, 77.0%, 5.3%, and 98.9%, respectively. The referral rate to specialists was 23.8% using FIB-4 ≥1.30. "FIB-4 ≥1.3 in subjects <65 years and FIB-4 ≥2.0 in subjects ≥65 years" showed higher PPV (6.7%) and lower referral rate (17.1%) compared with FIB-4 ≥1.3, but the sensitivity (54.5%) did not show adequate diagnostic capability as a noninvasive test for diagnosing VCTE-derived LSM ≥8 kPa.

Conclusions: Acknowledging the selection bias in hepatology centers, we undertook this prospective health check-up study. Although the FIB-4 index proves to be a convenient marker, it might not perform well as a primary screening tool for liver fibrosis in the general population (UMIN Clinical Trials Registry No. UMIN000035188).

目的:多协会共识命名法引入了脂肪性肝病(SLD),并将其分为不同的亚分类,即代谢功能障碍相关脂肪性肝病(MASLD)、代谢功能障碍和酒精相关脂肪性肝病(MetALD)、酒精相关肝病(ALD)、特殊病因和隐源性。根据新定义,我们调查了这些疾病在健康体检者中的患病率。此外,我们还分析了纤维化-4(FIB-4)指数和振动控制瞬态弹性成像(VCTE)得出的 MASLD 肝脏硬度测量(LSM)的分布情况:在这项横断面研究中,纳入了 6530 名在日本接受健康检查的受试者。对所有 6530 名受试者进行了常规 B 型超声波检查,并对患有 MASLD 的受试者进行了 VCTE 检查:结果:SLD 患病率为 39.5%,其中 MASLD 占 28.7%,MetALD 占 8.6%,ALD 占 1.2%,特殊病因 SLD 占 0.3%,隐源性 SLD 占 0.7%。VCTE 导出的 LSM ≥8 kPa 的受试者占 MASLD 的 2.1%。FIB-4 ≥1.3显示,诊断VCTE衍生的LSM≥8 kPa的敏感性、特异性、阳性预测值(PPV)和阴性预测值分别为60.6%、77.0%、5.3%和98.9%。使用 FIB-4 ≥1.30 的专家转诊率为 23.8%。"结论:考虑到肝病中心的选择偏差,我们开展了这项前瞻性健康体检研究。尽管 FIB-4 指数被证明是一种方便的标记物,但它可能无法很好地作为普通人群肝纤维化的初筛工具(UMIN 临床试验注册编号:UMIN000035188)。
{"title":"Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up.","authors":"Yuji Ogawa, Wataru Tomeno, Yasushi Imamura, Masaru Baba, Takato Ueno, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Takaomi Kessoku, Yasushi Honda, Kazuo Notsumata, Hirotoshi Fujikawa, Megumi Kaai, Kento Imajo, Miwa Kawanaka, Hideyuki Hyogo, Mitsurou Hisatomi, Mamiko Takeuchi, Taku Hakamada, Takashi Honda, Miwa Tatsuta, Asahiro Morishita, Shigeru Mikami, Ken Furuya, Noriaki Manabe, Tomoari Kamada, Takumi Kawaguchi, Masato Yoneda, Satoru Saito, Atsushi Nakajima","doi":"10.1111/hepr.14117","DOIUrl":"https://doi.org/10.1111/hepr.14117","url":null,"abstract":"<p><strong>Aims: </strong>The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), alcohol-associated liver disease (ALD), specific etiology, and cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check-ups. Additionally, we analyzed the distribution of Fibrosis-4 (FIB-4) index and vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM) for MASLD.</p><p><strong>Methods: </strong>In this cross-sectional study, 6530 subjects undergoing a health check-up in Japan were included. Conventional B-mode ultrasound was carried out on all 6530 subjects, and those with MASLD underwent VCTE.</p><p><strong>Results: </strong>The prevalence of SLD was 39.5%, comprising MASLD 28.7%, MetALD 8.6%, ALD 1.2%, specific etiology SLD 0.3%, and cryptogenic SLD 0.7%. Subjects with VCTE-derived LSM ≥8 kPa constituted 2.1% of MASLD. FIB-4 ≥1.3 showed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value for diagnosing VCTE-derived LSM ≥8 kPa were 60.6%, 77.0%, 5.3%, and 98.9%, respectively. The referral rate to specialists was 23.8% using FIB-4 ≥1.30. \"FIB-4 ≥1.3 in subjects <65 years and FIB-4 ≥2.0 in subjects ≥65 years\" showed higher PPV (6.7%) and lower referral rate (17.1%) compared with FIB-4 ≥1.3, but the sensitivity (54.5%) did not show adequate diagnostic capability as a noninvasive test for diagnosing VCTE-derived LSM ≥8 kPa.</p><p><strong>Conclusions: </strong>Acknowledging the selection bias in hepatology centers, we undertook this prospective health check-up study. Although the FIB-4 index proves to be a convenient marker, it might not perform well as a primary screening tool for liver fibrosis in the general population (UMIN Clinical Trials Registry No. UMIN000035188).</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection. 持续性急性肾损伤:肝脏切除术患者术后的影响和预测因素。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-04 DOI: 10.1111/hepr.14119
Shunsuke Doi, Satoshi Yasuda, Minako Nagai, Kota Nakamura, Yasuko Matsuo, Taichi Terai, Yuichiro Kohara, Takeshi Sakata, Masayuki Sho

Aim: Persistent acute kidney injury (AKI) has not been investigated in patients undergoing liver resection. We aimed to identify the predictors of persistent AKI, its effect on postoperative outcomes and long-term renal function in patients following liver resection, and its impact on survival in patients with hepatocellular carcinoma (HCC).

Methods: We examined 990 patients who underwent liver resection, including a subgroup analysis of 384 patients with curative resection for initial HCC. Persistent AKI was defined as residual impairment of serum creatinine ≥ 0.3 mg/dL or ≥50% from baseline 1 month after surgery.

Results: The persistent AKI group had significantly worse postoperative outcomes, including overall morbidity, major morbidity, longer hospital stay, and 90-day mortality. In the subgroup analysis of patients with HCC, persistent AKI was associated with a significantly poorer overall survival (OS) rate (p < 0.001), and the multivariate analysis confirmed persistent AKI as an independent poor prognostic factor for OS (p = 0.005). The long-term postoperative estimated glomerular filtration rate decline was significantly greater in the persistent AKI group than in the no AKI and transient AKI groups (p < 0.001 for both). Chronic kidney disease, albumin-bilirubin grade ≥2, and anatomical resection were independent predictors of persistent AKI (p = 0.001, p = 0.039, and p = 0.015, respectively).

Conclusions: Persistent AKI adversely affects postoperative outcomes and long-term renal function in patients undergoing liver resection. Furthermore, it is associated with poor prognosis in patients with HCC. Therapeutic strategies to prevent persistent AKI are critical for improving postoperative outcomes in these patients.

目的:尚未对肝脏切除术患者的持续性急性肾损伤(AKI)进行研究。我们旨在确定持续性 AKI 的预测因素、其对肝切除术后患者的术后效果和长期肾功能的影响,以及其对肝细胞癌(HCC)患者生存期的影响:我们对990名接受肝脏切除术的患者进行了研究,其中包括对384名因最初的HCC而接受治愈性切除术的患者进行的亚组分析。持续性 AKI 的定义是术后 1 个月血清肌酐残留损伤≥ 0.3 mg/dL 或比基线≥50%:结果:持续性 AKI 组患者的术后预后明显较差,包括总发病率、主要发病率、住院时间和 90 天死亡率。在对 HCC 患者进行的亚组分析中,持续性 AKI 与较差的总生存率(OS)明显相关(p 结论:持续性 AKI 对 HCC 患者的术后预后有不利影响:持续性 AKI 会对肝切除术患者的术后效果和长期肾功能产生不利影响。此外,它还与 HCC 患者的不良预后有关。预防持续性 AKI 的治疗策略对于改善这些患者的术后预后至关重要。
{"title":"Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection.","authors":"Shunsuke Doi, Satoshi Yasuda, Minako Nagai, Kota Nakamura, Yasuko Matsuo, Taichi Terai, Yuichiro Kohara, Takeshi Sakata, Masayuki Sho","doi":"10.1111/hepr.14119","DOIUrl":"https://doi.org/10.1111/hepr.14119","url":null,"abstract":"<p><strong>Aim: </strong>Persistent acute kidney injury (AKI) has not been investigated in patients undergoing liver resection. We aimed to identify the predictors of persistent AKI, its effect on postoperative outcomes and long-term renal function in patients following liver resection, and its impact on survival in patients with hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>We examined 990 patients who underwent liver resection, including a subgroup analysis of 384 patients with curative resection for initial HCC. Persistent AKI was defined as residual impairment of serum creatinine ≥ 0.3 mg/dL or ≥50% from baseline 1 month after surgery.</p><p><strong>Results: </strong>The persistent AKI group had significantly worse postoperative outcomes, including overall morbidity, major morbidity, longer hospital stay, and 90-day mortality. In the subgroup analysis of patients with HCC, persistent AKI was associated with a significantly poorer overall survival (OS) rate (p < 0.001), and the multivariate analysis confirmed persistent AKI as an independent poor prognostic factor for OS (p = 0.005). The long-term postoperative estimated glomerular filtration rate decline was significantly greater in the persistent AKI group than in the no AKI and transient AKI groups (p < 0.001 for both). Chronic kidney disease, albumin-bilirubin grade ≥2, and anatomical resection were independent predictors of persistent AKI (p = 0.001, p = 0.039, and p = 0.015, respectively).</p><p><strong>Conclusions: </strong>Persistent AKI adversely affects postoperative outcomes and long-term renal function in patients undergoing liver resection. Furthermore, it is associated with poor prognosis in patients with HCC. Therapeutic strategies to prevent persistent AKI are critical for improving postoperative outcomes in these patients.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd–Chiari syndrome in Japan 日本特发性门静脉高压症、肝外门静脉阻塞和巴德-卡氏综合征的诊断和治疗指南。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-04 DOI: 10.1111/hepr.14118
Yoshihiro Furuichi, Masayoshi Kage, Masayuki Ohta, Satoko Ohfuji, Hideyuki Sasaki, Hisashi Hidaka, Hiroshi Yoshida, Tatsuya Kanto, Hironori Kusano, Tomohiko Akahoshi, Katsutoshi Obara, Makoto Hashizume, Yukio Kuniyoshi, Takumi Kawaguchi, Hironao Okubo, Tsuyoshi Ishikawa, Masashi Hirooka, Yasuko Iwakiri, Masaki Nio, Atsushi Tanaka

This is the English version of the guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd–Chiari syndrome, which were established and revised in 2018 by the Aberrant Portal Hemodynamics Study Group under the jurisdiction of the Ministry of Health, Labor, and Welfare in Japan. These guidelines are excerpts, and the full version consists of 86 clinical questions and explanations, totaling 183 pages in Japanese.

这是特发性门静脉高压症、肝外门静脉梗阻和Budd-Chiari综合征诊断和治疗指南的英文版,由日本厚生劳动省管辖的门静脉血流动力学异常研究小组于2018年制定和修订。这些指南为节选,完整版包括 86 个临床问题和解释,日文版共 183 页。
{"title":"Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd–Chiari syndrome in Japan","authors":"Yoshihiro Furuichi,&nbsp;Masayoshi Kage,&nbsp;Masayuki Ohta,&nbsp;Satoko Ohfuji,&nbsp;Hideyuki Sasaki,&nbsp;Hisashi Hidaka,&nbsp;Hiroshi Yoshida,&nbsp;Tatsuya Kanto,&nbsp;Hironori Kusano,&nbsp;Tomohiko Akahoshi,&nbsp;Katsutoshi Obara,&nbsp;Makoto Hashizume,&nbsp;Yukio Kuniyoshi,&nbsp;Takumi Kawaguchi,&nbsp;Hironao Okubo,&nbsp;Tsuyoshi Ishikawa,&nbsp;Masashi Hirooka,&nbsp;Yasuko Iwakiri,&nbsp;Masaki Nio,&nbsp;Atsushi Tanaka","doi":"10.1111/hepr.14118","DOIUrl":"10.1111/hepr.14118","url":null,"abstract":"<p>This is the English version of the guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd–Chiari syndrome, which were established and revised in 2018 by the Aberrant Portal Hemodynamics Study Group under the jurisdiction of the Ministry of Health, Labor, and Welfare in Japan. These guidelines are excerpts, and the full version consists of 86 clinical questions and explanations, totaling 183 pages in Japanese.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between antibiotic use and cardiovascular diseases in metabolic dysfunction-associated steatotic liver disease: A nationally representative retrospective cohort study. 代谢功能障碍相关脂肪肝患者使用抗生素与心血管疾病之间的关系:一项具有全国代表性的回顾性队列研究。
IF 3.9 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-30 DOI: 10.1111/hepr.14115
Ju Hyun Kang, Sun Jae Park, Seogsong Jeong, Young Jun Park, Hye Jun Kim, Jihun Song, Jiwon Choi, Sangwoo Park, Jaewon Kim, Hyeokjong Lee, Jooyoung Chang, Joung Sik Son, Sang Min Park

Aim: Various subcategories for steatotic liver disease (SLD) were proposed globally. Previous studies suggested a heightened risk of cardiovascular diseases (CVD) with prolonged antibiotic exposure and metabolic dysfunction-associated SLD (MASLD), respectively. This study investigates the impact of antibiotic usage on CVD in MASLD patients.

Methods: From the Korean National Health Insurance Service database, 276 520 adults aged 40 and older were included. Antibiotic exposure was defined by the cumulative prescription days and the number of classes. Participants were categorized into no SLD and MASLD groups. Hepatic steatosis was defined by using the fatty liver index ≥60. From 2013 to 2019, 16 197 CVD cases were recorded. A multivariate Cox model, adjusting for covariates, assessed adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD risk associated with MASLD and antibiotic prescriptions.

Results: The group with ≥91 days of antibiotics prescribed and MASLD showed a significantly increased risk of CVD (aHR, 1.56; 95% CI, 1.39-1.74) compared with antibiotic non-users without SLD. Furthermore, the group with ≥4 classes of antibiotics prescribed and MASLD had an elevated risk of CVD (aHR, 1.49; 95% CI, 1.34-1.66) compared with antibiotic non-users without SLD. Consistent results were observed in several sensitivity analyses.

Conclusions: Our study identified prolonged antibiotic exposure may be a factor that increases the risk of CVD in MASLD patients. These findings suggest an epidemiological basis for the therapeutic application of antibiotics in MASLD patients, and emphasize the need for further studies to deepen the understanding of these intricate relationships.

目的:全球范围内对脂肪性肝病(SLD)提出了多种分类。先前的研究表明,长期接触抗生素和代谢功能障碍相关性脂肪肝(MASLD)分别增加了心血管疾病(CVD)的风险。本研究调查了抗生素的使用对 MASLD 患者心血管疾病的影响:从韩国国民健康保险服务数据库中纳入了 276 520 名 40 岁及以上的成年人。抗生素接触的定义是累计处方天数和种类数。参与者被分为无 SLD 组和 MASLD 组。肝脏脂肪变性的定义是脂肪肝指数≥60。从2013年到2019年,共记录了16 197例心血管疾病病例。在调整协变量后,采用多变量Cox模型评估了与MASLD和抗生素处方相关的心血管疾病风险的调整后危险比(aHRs)和95%置信区间(CIs):与不使用抗生素且无 SLD 的人群相比,使用抗生素≥91 天且患有 MASLD 的人群患心血管疾病的风险明显增加(aHR, 1.56; 95% CI, 1.39-1.74)。此外,与不使用抗生素且无 SLD 的人群相比,使用≥4 类抗生素且有 MASLD 的人群患心血管疾病的风险更高(aHR,1.49;95% CI,1.34-1.66)。在几项敏感性分析中观察到了一致的结果:我们的研究发现,长期接触抗生素可能是增加MASLD患者心血管疾病风险的一个因素。这些发现为在MASLD患者中应用抗生素进行治疗提供了流行病学依据,并强调了进一步研究以加深对这些错综复杂关系的理解的必要性。
{"title":"Association between antibiotic use and cardiovascular diseases in metabolic dysfunction-associated steatotic liver disease: A nationally representative retrospective cohort study.","authors":"Ju Hyun Kang, Sun Jae Park, Seogsong Jeong, Young Jun Park, Hye Jun Kim, Jihun Song, Jiwon Choi, Sangwoo Park, Jaewon Kim, Hyeokjong Lee, Jooyoung Chang, Joung Sik Son, Sang Min Park","doi":"10.1111/hepr.14115","DOIUrl":"https://doi.org/10.1111/hepr.14115","url":null,"abstract":"<p><strong>Aim: </strong>Various subcategories for steatotic liver disease (SLD) were proposed globally. Previous studies suggested a heightened risk of cardiovascular diseases (CVD) with prolonged antibiotic exposure and metabolic dysfunction-associated SLD (MASLD), respectively. This study investigates the impact of antibiotic usage on CVD in MASLD patients.</p><p><strong>Methods: </strong>From the Korean National Health Insurance Service database, 276 520 adults aged 40 and older were included. Antibiotic exposure was defined by the cumulative prescription days and the number of classes. Participants were categorized into no SLD and MASLD groups. Hepatic steatosis was defined by using the fatty liver index ≥60. From 2013 to 2019, 16 197 CVD cases were recorded. A multivariate Cox model, adjusting for covariates, assessed adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD risk associated with MASLD and antibiotic prescriptions.</p><p><strong>Results: </strong>The group with ≥91 days of antibiotics prescribed and MASLD showed a significantly increased risk of CVD (aHR, 1.56; 95% CI, 1.39-1.74) compared with antibiotic non-users without SLD. Furthermore, the group with ≥4 classes of antibiotics prescribed and MASLD had an elevated risk of CVD (aHR, 1.49; 95% CI, 1.34-1.66) compared with antibiotic non-users without SLD. Consistent results were observed in several sensitivity analyses.</p><p><strong>Conclusions: </strong>Our study identified prolonged antibiotic exposure may be a factor that increases the risk of CVD in MASLD patients. These findings suggest an epidemiological basis for the therapeutic application of antibiotics in MASLD patients, and emphasize the need for further studies to deepen the understanding of these intricate relationships.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepatology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1